Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Efficacy and Tolerability of DITROPAN® XL (Oxybutynin Chloride) Versus DETROL® LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
This study has been completed.
Sponsored by: Alza Corporation, DE, USA
Information provided by: Alza Corporation, DE, USA
ClinicalTrials.gov Identifier: NCT00293839
  Purpose

The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.


Condition Intervention Phase
Urinary Incontinence
Drug: oxybutynin chloride
Phase III

MedlinePlus related topics: Urinary Incontinence
Drug Information available for: Tolterodine Chlorides Tolterodine tartrate Oxybutynin Oxybutynin chloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: Comparison of the Efficacy and Tolerability of DITROPAN® XL and DETROL® LA in the Treatment of Overactive Bladder

Further study details as provided by Alza Corporation, DE, USA:

Primary Outcome Measures:
  • The number of weekly urge urinary incontinence (Urge-UI) episodes at week 12, adjusted for the baseline value

Secondary Outcome Measures:
  • The number of total urinary incontinence (Total-UI) episodes at week 12; Void frequency at week 12; Urge-UI ,Total-UI, and Void frequence at weeks 2, 4, and 8; tolerability of the treatments during the 12-week treatment phase.

Estimated Enrollment: 750
Study Start Date: November 2001
Estimated Study Completion Date: December 2002
Detailed Description:

The objective of this study is to compare the efficacy and tolerability of DITROPAN® XL 10 mg once-daily and DETROL® LA 4 mg once-daily in the reduction of urge urinary incontinence episodes in female patients with overactive bladder. This is a multicenter, randomized, double-blind, parallel-group study with two active treatments. Screened patients are qualified for the study based on information obtained from seven consecutive 24-hour urinary diaries completed during the Baseline Week, and other eligibility criteria. Qualifying patients receive 12 weeks of treatment with DITROPAN® XL or DETROL® LA, with clinical visits at the end of Weeks 2, 4, 8, and 12. Safety evaluations during the study include the collection of adverse events, laboratory tests including blood chemistry and urinalysis, physical examinations, vital signs (blood pressure and heart rate) and post-void residual urine volume.

Over-encapsulated DITROPAN® XL, 10 mg tablets once-daily by mouth or over-encapsulated DETROL® LA, 4 mg capsules once daily by mouth. The treatment phase of the study runs for 12 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants who are able to differentiate urinary incontinence episodes associated with urgency from urinary incontinence episodes not associated with urgency
  • During the 7 day baseline period have 21 to 60 urge urinary incontinence (Urge-UI) episodes, a greater number of Urge-UI episodes than urinary incontinence not associated with urge, and an average of 10 or more voids per 24 hours
  • Are in good general health as determined by medical history, physical examination (general, genital, pelvic, and rectal), laboratory tests and urinalysis
  • If taking antihypertension medication, must be on a stable dose
  • And if of child-bearing potential, practicing an acceptable method of birth control, and must have a negative pregnancy test at Visit 2 and Visit 3

Exclusion Criteria:

  • Participants with known, treatable genitourinary conditions (identified on history or on examination) that may cause incontinence (e.g., urinary tract infection, interstitial cystitis, urinary tract obstruction, urethral diverticulum, bladder tumor, bladder stone)
  • Have given birth or have had pelvic, vaginal or bladder surgery less than 6 months before study enrollment
  • With a second post-void residual urine volume > 150 mL at the time of screening (determined by abdominal ultrasound)
  • With significant medical problems or other organ abnormality that places them at risk from participating in the study or at a significant risk of developing complete urinary retention
  • With significant impairment of the liver or kidneys as determined by laboratory assessments or hematuria (red blood cells in microscopic urinalysis)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00293839

Sponsors and Collaborators
Alza Corporation, DE, USA
Investigators
Study Director: Alza Corporation Clinical Trial Alza Corporation, DE, USA
  More Information

Publications of Results:
Study ID Numbers: CR004570
Study First Received: February 16, 2006
Last Updated: April 6, 2007
ClinicalTrials.gov Identifier: NCT00293839  
Health Authority: United States: Food and Drug Administration

Keywords provided by Alza Corporation, DE, USA:
overactive
bladder

Study placed in the following topic categories:
Oxybutynin
Signs and Symptoms
Urinary Bladder, Overactive
Cystocele
Urologic Diseases
Urination Disorders
Urinary Bladder Diseases
Urinary Incontinence
Mandelic Acids
Tolterodine

Additional relevant MeSH terms:
Parasympatholytics
Anti-Infective Agents
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Infective Agents, Urinary
Renal Agents
Cholinergic Agents
Pharmacologic Actions
Muscarinic Antagonists
Urological Manifestations
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on January 14, 2009